Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment.
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major obstetric health problems. Higher levels of T-helper (Th) 1 (proinflammatory) cytokines have been observed in pregnancies complicated with PE and IUGR; this is in contrast to the predominant Th2 (anti-inflammatory) cytokine environment found in uncomplicated pregnancies. Myostatin is best known as a negative regulator of muscle development and reportedly has a role in fat deposition, glucose metabolism, and cytokine modulation (outside the placenta). Myostatin concentrations in plasma and protein expression in placental tissue are significantly higher in women with PE. Expression of myostatin in IUGR and PE-IUGR and the effect of this protein on the cytokine production from the placenta is unknown. In the current study, significant differences were identified in the expression of myostatin in pregnancies complicated with IUGR, PE, and PE with IUGR. Furthermore, cytokine production by first-trimester placental tissues was altered following myostatin treatment.
The University of Queensland Centre for Clinical Research, Brisbane, Australia.
Hassendrini N
HN
Peiris
Department of Obstetrics & Gynaecology, The University of Melbourne, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
Harry
H
Georgiou
Department of Obstetrics & Gynaecology, The University of Melbourne, Mercy Hospital for Women, Heidelberg, Victoria, Australia Department of Obstetrics and Gynaecology, Obstetrics, Nutrition and Endocrinology Group, University of Melbourne, Melbourne, Victoria, Australia.
Martha
M
Lappas
Department of Obstetrics & Gynaecology, The University of Melbourne, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
Tu'uhevaha
T
Kaitu'u-Lino
The University of Queensland Centre for Clinical Research, Brisbane, Australia.
Carlos
C
Salomón
The University of Queensland Centre for Clinical Research, Brisbane, Australia.
Kanchan
K
Vaswani
The University of Queensland Centre for Clinical Research, Brisbane, Australia.
Gregory E
GE
Rice
The University of Queensland Centre for Clinical Research, Brisbane, Australia murray.mitchell@uq.edu.au.
Murray D
MD
Mitchell
D000328:Adult; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood* / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism*; D055435:Myostatin / Q000097:blood* / Q000276:immunology / Q000494:pharmacology*; D010920:Placenta / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D011225:Pre-Eclampsia / Q000097:blood* / Q000276:immunology; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D046509:Tissue Culture Techniques; D015854:Up-Regulation
D016207:Cytokines; D018836:Inflammation Mediators; C525911:MSTN protein, human; D055435:Myostatin
Growth Differentiation Factor 8 (GDF-8); intrauterine growth restriction; myostatin; placenta; preeclampsia